Releases
See all
Releases
29. October, 2024
Cessatech company presentation – 29 Oct
Watch the recorded company presentation from Nordnet, and a new update from Ventis Pharma....
Releases
26. August, 2024
Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001
Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding...
Releases
12. August, 2024
Cessatech extends Loan Facility Agreement to DKK 10 million…
Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the...
Releases
5. July, 2024
Anders Dyhr Dombernowsky-Toft appointed to the Board of Directors
Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the...
Releases
28. June, 2024
New data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001
On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation...
Facts about Children
See all
Facts
18. March, 2024
Acute pain treatment – large unmet need, paediatrics receive least…mainly due to inadequate solutions
More than 20 million children annually, alone in Europe, are subject to acute pain...
Facts
12. February, 2024
Treating children is not just like treating small adults
Giving medicine to children can’t be a one-size-fits-all approach. Their changing anatomy and...
Facts
25. August, 2023
New findings supporting CT001
Based on new findings in a 2023 meta-analysis by Fjendbo Galili et al., which...
Facts
15. March, 2022
Off-label use of medication in children continue to be the rule rather than the exception…
A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...
Facts
3. March, 2022
Physical restraint of children in 79% of Scandinavian emergency departments
Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...
Experience
Proven track-record within drug development and product launches, in Europe, US and Asia.
The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.
Team
Lead Asset
CT001 – Nasal spray
Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.
See detailsStay up to date!
Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.